Miconazole Inhibitors
1 drugsAbout Miconazole
Miconazole is an antifungal drug target relevant for treating fungal infections. It is the active ingredient in at least one FDA-approved drug, highlighting its clinical significance.
Pharmacological modulation of Miconazole is achievable and therapeutically beneficial, as evidenced by the approved drug VUSION. There is currently no genetic evidence directly linking Miconazole to specific diseases in this dataset.
Miconazole is targeted by one FDA-approved drug, VUSION (Viatris), a small molecule. The therapeutic area associated with Miconazole-targeting drugs is classified as 'Other', related to its antifungal properties.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Endometrial Cancer with only 1 trials.
Top Miconazole Drugs
Viatris is the only company with an approved drug targeting Miconazole.
Low competition suggests easier market entry, but also indicates potential challenges in the target space.
Miconazole Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Miconazole, using small molecule modality.
The modality landscape suggests an opportunity to explore other modalities like antibodies or peptides.
Miconazole Clinical Trials 6 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 2 | 2 | 0 | 0 | 100% |
| Phase 3 | 2 | 1 | 0 | 1 | 100% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Miconazole Drug Approval Timeline (2006 - 2006)
The first and most recent drug approval for Miconazole was VUSION in 2006.
The lack of recent approvals indicates potential saturation or challenges in developing new Miconazole-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (12 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 12 clinical trials targeting Miconazole.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities